艾昆纬 IQV 深 沪
已收盘 01-30 16:00:00 美东时间
230.15
-5.470
-2.32%
华盛通- 最 高234.865
- 今 开234.41
- 成交量 146.39万股
- 最 低 228.67
- 昨 收 235.62
- 总市值 391.26亿
- 52周最高 247.045
- 市盈率 静 30.74
- 换手率 0.86%
- 52周最低 134.645
- 委 比 0.00%
- 总股本 1.70亿
- 历史最高 285.61
- 量 比 1.22
- 振 幅 2.63%
- 历史最低 81.79
- 每 手 1
- 风险率 29.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 1-Novo's Wegovy pill surpasses 26,000 prescriptions in second full week
UPDATE 1-Novo's Wegovy pill surpasses 26,000 prescriptions in second full week Adds background in paragraphs 3 and 6 Jan 30 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill hit over 26,000 U.S. prescriptions in the second full week after its launch, IQVIA data shared by an analyst on Friday showed. I
01-30 20:55
诺和诺德口服版司美格鲁肽处方量突破2.6万张
分析师周五分享的艾昆纬数据显示，诺和诺德口服版司美格鲁肽（Wegovy）在美国上市后第二个完整交易周的处方量突破 2.6 万张。 减肥药市场竞争激烈，投...
01-30 20:45
IQVIA and Boehringer Ingelheim Launch Global Commercial Data Collaboration
IQVIA and Boehringer Ingelheim Launch Global Commercial Data Collaboration IQVIA Holdings Inc. has announced a strategic long-term collaboration with Boehringer Ingelheim to transform Boehringer’s global commercial data foundation. Through this partnership, Boehringer Ingelheim will leverage IQVIA’s
01-29 21:01
诺和诺德为司美格鲁肽类药物投入的美国广告费用是礼来的两倍
登录新浪财经APP 搜索【信披】查看更多考评等级 路透社获取的最新数据显示，为争夺市场份额，丹麦制药企业诺和诺德 2025 年前 9 个月...
01-28 20:21
UPDATE 1-Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch
UPDATE 1-Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch Adds background in paragraphs 5, 7 and 8, shares in paragraph 6 Jan 23 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared
01-23 20:47
Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch
Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch Jan 23 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed. Investors are closely watching prescript
01-23 20:28
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
TD Cowen Maintains Hold on IQVIA Hldgs, Raises Price Target to $245
TD Cowen analyst Charles Rhyee maintains IQVIA Hldgs (NYSE:IQV) with a Hold and raises the price target from $215 to $245.
01-23 00:56
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
UBS Maintains Buy on IQVIA Hldgs, Raises Price Target to $280
UBS analyst Dan Leonard maintains IQVIA Hldgs (NYSE:IQV) with a Buy and raises the price target from $250 to $280.
01-09 00:31
